In view of the balanceddistribution of therapies for other cardiovascular comorbidities, the lack of differencesin blood pressure between randomized groups, and in view of the long-term outcomes ofRACE-3,17 where a randomizedintervention with high use of statins, Mineralocorticoid receptor antagonists (MRAs), andnurse-led care did not improve five-year outcomes (neither for recurrent AF nor for MACCE,recently presented at EHRA 2021), it is unlikely that undetected differences in thistreatment domain can explain the differences in outcomes observed in EAST-AFNET 4. Here, NR3C2 is linked to atrial fibrillation.